Perindopril, a new angiotensin converting enzyme inhibitor--clinical pharmacological studies in healthy subjects.
Perindopril is a new angiotensin converting enzyme (ACE) inhibitor which is activated after hydrolysis in vivo to a diacid (S9780). Oral administration of perindopril (1-16 mg) to groups of 6 healthy males led to a long lasting and dose-elated inhibition of plasma ACE and rises in plasma renin activity with no evidence of accumulation of drug or effect. At higher doses there was a modest fall in blood pressure. S9780 given intravenously in doses of 1,2 or 4 mg caused an immediate inhibition of plasma ACE. The concentration of S9780 in plasma which led to 50% inhibition of plasma ACE was 1.55 +/- 1.14 ng/ml (mean +/- S.D.). Clinical trials with 2-8 mg once daily in essential hypertension are currently in progress.
D000284:Administration, Oral; D000806:Angiotensin-Converting Enzyme Inhibitors; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D007275:Injections, Intravenous; D007700:Kinetics; D007703:Peptidyl-Dipeptidase A / Q000097:blood; D020913:Perindopril
D000806:Angiotensin-Converting Enzyme Inhibitors; D007211:Indoles; D007703:Peptidyl-Dipeptidase A; D020913:Perindopril